CTI BioPharma Corp investor relations material

CTI BioPharma Corp. is a biopharmaceutical company that acquires, develops and commercializes novel targeted therapies for blood-related cancers in the United States. The Company's product candidates include bevacizumab/dexrazoxane, rapamycin and bortezomib/dexrazoxane that have demonstrated efficacy in preclinical and clinical studies.